EGFR tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, are targeted therapies, used as first-line treatments for patients with NSCLC harboring EGFR mutations (Shukuya et al., 2011; De Mello et al., 2016). This evidence concerns the gene EGFR and non-small cell lung carcinoma.